Xtant Medical Announces Closing of $15 Million Private Placement
2023年7月7日 - 9:00PM
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global
medical technology company focused on surgical solutions for the
treatment of spinal disorders, today announced the closing of its
previously announced $15 million private placement with accredited
investors. The Company sold 20 million shares of common stock at a
purchase price of $0.75 per share. After deducting fees and other
estimated offering expenses, the Company received net proceeds of
approximately $14.2 million.
The Company expects to use the net proceeds from
the private placement for working capital and other general
corporate purposes.
Craig-Hallum Capital Group LLC served as sole
placement agent for the private placement.
The private placement is complete and was made
pursuant to the exemption from securities registration under
Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule
506 of Regulation D as promulgated by the United States Securities
and Exchange Commission (SEC) and the shares sold in the private
placement may not be offered or sold in the United States absent
registration with the SEC or an applicable exemption from such
registration requirements. The Company has agreed to file a
registration statement with the SEC covering the resale of the
shares of common stock issued in the private placement.
This release shall not constitute an offer to
sell or the solicitation of an offer to buy nor shall there be any
sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or other jurisdiction.
About Xtant Medical Holdings,
Inc.
Xtant Medical Holdings, Inc.
(www.xtantmedical.com) is a global medical technology company
focused on the design, development, and commercialization of a
comprehensive portfolio of orthobiologics and spinal implant
systems to facilitate spinal fusion in complex spine, deformity and
degenerative procedures. Xtant people are dedicated and talented,
operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and
registered trademarks of Xtant Medical Holdings, Inc. or its
affiliates, registered as indicated in the United States, and in
other countries. All other trademarks and trade names referred to
in this release are the property of their respective owners.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
that are predictive in nature, that depend upon or refer to future
events or conditions, or that include words such as “intends,”
‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’
‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going
forward,” similar expressions or the negative thereof, and the use
of future dates. Forward-looking statements in this release include
the Company’s expectations regarding the anticipated use of net
proceeds from the private placement. The Company cautions that its
forward-looking statements by their nature involve risks and
uncertainties, and actual results may differ materially depending
on a variety of important factors, including, among others: risks
and uncertainties surrounding the private placement; the Company’s
future operating results and financial performance; its ability to
increase or maintain revenue; risks associated with its recent
acquisition of the Coflex product line; possible future impairment
charges to long-lived assets and goodwill and write-downs of excess
inventory if revenues decrease; the ability to remain competitive;
the ability to innovate, develop and introduce new products; the
ability to engage and retain new and existing independent
distributors and agents and qualified personnel and the Company’s
dependence on key independent agents for a significant portion of
its revenue; the effect of COVID-19, labor and hospital staffing
shortages on the Company’s business, operating results and
financial condition, especially when they affect key markets; the
Company’s ability to implement successfully its future growth
initiatives and risks associated therewith; the effect of
inflation, increased interest rates and other recessionary factors
and supply chain disruptions; the effect of product sales mix
changes on the Company’s financial results; government and
third-party coverage and reimbursement for Company products; the
ability to obtain and maintain regulatory approvals and comply with
government regulations; the effect of product liability claims and
other litigation to which the Company may be subject; the effect of
product recalls and defects; the ability to obtain and protect
Company intellectual property and proprietary rights and operate
without infringing the rights of others; the ability to service
Company debt, comply with its debt covenants and access additional
indebtedness; the ability to obtain additional financing on
favorable terms or at all; and other factors. Additional risk
factors are contained in the Company’s Annual Report on Form 10-K
for the year ended December 31, 2022 filed with the SEC on March 8,
2023 and subsequent SEC filings by the Company, including without
limitation its most recent Quarterly Report on Form 10-Q for the
quarterly period ended March 31, 2023 anticipated to be filed with
the SEC. Investors are encouraged to read the Company’s filings
with the SEC, available at www.sec.gov, for a discussion of these
and other risks and uncertainties. The Company undertakes no
obligation to release publicly any revisions to any forward-looking
statements to reflect events or circumstances after the date hereof
or to reflect the occurrence of unanticipated events, except as
required by law. All forward-looking statements attributable to the
Company or persons acting on its behalf are expressly qualified in
their entirety by this cautionary statement.
Investor Relations Contact
David CareyLazar FINNPh: 212-867-1762Email:
david.carey@finnpartners.com
Xtant Medical (AMEX:XTNT)
過去 株価チャート
から 4 2024 まで 5 2024
Xtant Medical (AMEX:XTNT)
過去 株価チャート
から 5 2023 まで 5 2024